Analysis of Serum Antibodies in Patients Suspected of Having Inflammatory Bowel Disease

Troy D. Jaskowski,1* Christine M. Litwin,1,2 and Harry R. Hill1,2,3

Associated Regional and University Pathologists Institute for Clinical and Experimental Pathology1 and Departments of Pathology2 and Pediatrics and Medicine,3 University of Utah School of Medicine, Salt Lake City, Utah 84108

Received 27 January 2006/Returned for modification 2 March 2006/Accepted 23 March 2006

Inflammatory bowel disease (IBD) is the general term used for a heterogeneous group of intestinal disorders, including Crohn’s disease (CD) and ulcerative colitis (UC). Serological markers such as anti-Saccharomyces cerevisiae antibodies (ASCA) and atypical perinuclear antineutrophilic cytoplasmic antibody (atypical pANCA) have proven useful in the diagnosis and differentiation of CD and UC. Immunoglobulin A (IgA) antibody directed against the outer membrane protein C (OmpC) of Escherichia coli is said by one group to have clinical utility in diagnosing IBD, specifically in ASCA-negative CD patients. Our objective in this study was to compare the results obtained from two separate laboratories offering similar IBD tests using sera from suspected IBD patients. One hundred ninety-seven sera received for IBD testing were included in the study. The agreement between the two laboratories was 93.4% for ASCA IgA, 90.9% for ASCA IgG, and 87.8% for atypical pANCA IgG. There were 25 sera with ASCA-negative/OmpC-positive results reported by one laboratory. Thirteen of these 25 (52.0%) ASCA-negative/OmpC-positive sera were also atypical pANCA positive (9 as determined by both laboratories, 3 by one, and 1 by the other). Atypical pANCA antibody is found primarily in IBD patients with UC and colon-limited disease (Crohn’s colitis). We conclude that the ASCA and atypical pANCA assays showed good agreement between the two laboratories, but the data for ASCA-negative/OmpC-positive sera suggest that many (52.0%) of these patients were more likely to have had UC or Crohn’s colitis based on the presence of an atypical pANCA.

Crohn’s disease (CD) and ulcerative colitis (UC) are the two major forms of inflammatory bowel disease (IBD). Both CD and UC are chronic, affecting children and adults (men and women almost equally), and are most common in northern Europe and North America. The onset of CD and UC is usually between the ages of 15 and 30, with a second, smaller peak of incidence between the ages of 50 and 70 (4, 23). Approximately 20% of individuals with CD have a biological relative with some form of IBD, and several reports have noted an increase in the prevalence of CD and UC in various geographic regions (2, 17, 24, 36).

Although there are many theories about the etiology of CD and UC, none have been proven. Many of the symptoms of CD and UC are similar, and diagnosis is often difficult, time-consuming, and invasive. Since CD and UC are treated differently, correct diagnosis and differentiation are medically important.

Two serological markers have been found to have clinical utility in diagnosing IBD and aiding in the differentiation of CD from UC: anti-Saccharomyces cerevisiae antibody (ASCA) (immunoglobulin A [IgA] and/or IgG), using enzyme immunoassay (EIA) techniques, and antineutrophil cytoplasmic antibody (ANCA) (IgG) that demonstrates atypical perinuclear staining (pANCA), using indirect fluorescent-antibody assay (IFA) techniques. ASCA is directed against mannose sequences in the cell wall of Saccharomyces cerevisiae (26, 35) and is significantly more prevalent in patients with CD than in those with UC and healthy controls (15, 18, 19, 25, 31, 32, 35). ASCA IgA is found in 35 to 50% of patients with CD but in <1% of patients with UC. ASCA IgG is found in 50 to 80% of CD patients but only 20% of UC patients. Multiple studies have reported the simultaneous presence of ASCA IgA and IgG to be highly specific for CD (3, 31, 33). ASCA antibodies are currently identified using commercial or in-house-developed EIAs. Independent studies have shown differences in sensitivity and specificity between some of the ASCA EIAs that are currently available (13, 16, 20, 41).

The atypical pANCA (ethanol-positive/formalin-negative) IFA pattern seen in patients with UC and autoimmune hepatitis is directed against an antigen(s) on the inner side of the nuclear membrane of the neutrophil (37–39). One group has suggested that histone H1 is the target antigen associated with atypical pANCA (5), but histone H1 is not specific to neutrophils and histone H1 as a target is not supported by other researchers (37–39).

Atypical pANCA is found in 70% of patients with UC but in only 20% of patients with CD (8–10). Atypical pANCA has also been reported to be present in a subgroup of CD patients with colon-limited disease (12, 40). The “typical” pANCA pattern observed in vasculitis patients, using ethanol-fixed neutrophils, will convert to a cytoplasmic ANCA (cANCA) pattern on formalin-fixed neutrophils. These antibodies are usually directed against myeloperoxidase (MPO). In contrast, the “atypical” pANCA pattern found in IBD patients will not convert to a cANCA pattern on formalin-fixed neutrophils but rather exhibits an essentially negative pattern. ANCA systems that replace formalin-fixed neutrophils with an enzyme (DNase I) digest step are rarely used outside the group (the Cedars Sinai IBD group of Stephen R. Targan) that developed this method.

* Corresponding author. Mailing address: ARUP Institute for Clinical and Experimental Pathology, 500 Chipeta Way, Salt Lake City, UT 84108. Phone: (801) 583-2787, ext. 2817. Fax: (801) 584-5109. E-mail: jaskowtd@aruplab.com.
Detection of IgA antibody against the outer membrane porin C (OmpC) of *Escherichia coli* has been promoted as a way to identify patients with Crohn’s disease that are seronegative for ASCA (14). Thus far, independent studies have reported poor sensitivity for OmpC IgA in IBD, and false positives are common (6, 43).

Our objectives in this study were to compare the results obtained from two different reference laboratories that offer similar IBD tests using sera from suspected IBD patients.

**MATERIALS AND METHODS**

**Clinical samples.** One hundred ninety-seven consecutive sera from patients suspected of having IBD, sent to our laboratory for IBD testing, were included in the study. All patient sera were processed according to the University of Utah Institutional Review Board approved protocol no. 13433 and meet the Health Information Portability and Accountability Act patient confidentiality guidelines. Physicians of patients having ASCA-negative/OmpC-positive results as determined by Prometheus Laboratories were contacted by phone in an attempt to obtain the diagnosis.

**IBD immunoassays by ARUP Laboratories.** ASCA IgA and IgG were detected using EIAs purchased from INOVA Diagnostics (San Diego, CA). These assays were performed at Associated Regional and University Pathologists (ARUP) Laboratories (Salt Lake City, UT), an esoteric reference laboratory owned by the University of Utah, according to the manufacturer’s product insert. These assays have been approved by the Food and Drug Administration (FDA) for in vitro diagnostic use with patients suspected of having Crohn’s disease.

Atypical pANCA IgG was detected using ANCA IFA substrate slides purchased from INOVA Diagnostics. This assay utilizes the standard IFA method (ethanol- and formalin-fixed neutrophils) for detecting ANCA and is the most accepted and widely used method in detecting atypical pANCA (1, 11, 21, 22, 194) of these 18 sera (44.4%) were ASCA IgA positive, as determined by both laboratories (Table 4). The Prometheus ASCA IgG gave positive results as determined by ARUP (Table 2). One (no. 133) of these two sera was also positive for ASCA IgG, as determined by ARUP (Table 4). The Prometheus ASCA IgG gave negative results for 18 of the 32 positive sera (56.3%) detected by the ASCA IgG assay performed at ARUP (Table 2). In addition, eight (no. 14, 30, 113, 136, 138, 172, 193, and 194) of these 18 sera (44.4%) were ASCA IgA positive, as determined by both laboratories (Table 4).

**RESULTS**

The agreement between the two laboratories for the ASCA IgA was 93.4%, 90.9% for ASCA IgG and 87.8% for atypical pANCA IgG (Tables 1 to 3). The ASCA IgA assay performed at Prometheus gave positive results for 11 additional sera compared to the ASCA IgA performed at ARUP (Table 1). Nine of these 11 sera (81.8%; no. 57, 65, 68, 103, 158, 189, 195, 210, and 212) gave negative results for ASCA IgG, as determined by both laboratories (Table 4). There were two sera that were ASCA IgA negative as determined by Prometheus and that gave positive results as determined by ARUP (Table 2). One (no. 133) of these two sera was also positive for ASCA IgG, as determined by ARUP (Table 4). The Prometheus ASCA IgG gave negative results for 18 of the 32 positive sera (56.3%) detected by the ASCA IgG assay performed at ARUP (Table 2). In addition, eight (no. 14, 30, 113, 136, 138, 172, 193, and 194) of these 18 sera (44.4%) were ASCA IgA positive, as determined by both laboratories (Table 4).

The DNase digest method detected atypical pANCA (DNAse sensitive) in 22 sera in addition to the 33 that were in positive agreement with the standard IFA method (Table 3). The standard IFA method detected atypical pANCA (ethanol positive/formalin negative) in two sera that were negative by the DNase digest method (Table 3). We assessed these 24 discrepant atypical pANCA sera for IgG antibodies against

**TABLE 1. Comparison of results from two different laboratories for ASCA IgA by EIA in 197 patient sera**

| Prometheus ASCA IgA result | No. with ARUP ASCA IgA resulta |
|---------------------------|---------------------------------|
| Positive                  | 29                              |
| Negative                  | 2                               |

a Agreement, 93.4%.

**TABLE 2. Comparison of results from two different laboratories for ASCA IgG by EIA in 197 patient sera**

| Prometheus ASCA IgG result | No. with ARUP ASCA IgG resulta |
|---------------------------|---------------------------------|
| Positive                  | 14                              |
| Negative                  | 18                              |

a Agreement, 90.9%.

**TABLE 3. Comparison of results from two different laboratories for atypical pANCA IgG by IFA in 197 patient sera**

| Prometheus DNase 1 digest method result | No. with ARUP standard method resulta |
|----------------------------------------|-------------------------------------|
| Positive                               | 33                                  |
| Negative                               | 2                                   |

a Agreement, 87.8%.
TABLE 4. ASCA results for 29 discrepant sera from two different laboratories

| Sample no. | ARUP ASCA IgA | Prometheus ASCA IgA | ARUP ASCA IgG | Prometheus ASCA IgG |
|------------|---------------|---------------------|---------------|---------------------|
| 14         | +             | +                   | +             | +                   |
| 26         | –             | –                   | +             | –                   |
| 30         | +             | +                   | +             | –                   |
| 47         | –             | –                   | +             | –                   |
| 57         | –             | +                   | –             | –                   |
| 65         | –             | –                   | +             | –                   |
| 68         | –             | –                   | –             | –                   |
| 70         | –             | –                   | +             | –                   |
| 103        | –             | +                   | –             | –                   |
| 118        | –             | +                   | –             | –                   |
| 133        | +             | –                   | +             | –                   |
| 135        | +             | –                   | –             | +                   |
| 136        | +             | +                   | +             | +                   |
| 138        | +             | +                   | +             | –                   |
| 148        | –             | –                   | +             | –                   |
| 158        | –             | –                   | +             | –                   |
| 162        | –             | +                   | –             | –                   |
| 168        | –             | –                   | +             | –                   |
| 172        | +             | +                   | +             | –                   |
| 189        | –             | –                   | +             | –                   |
| 193        | +             | +                   | –             | +                   |
| 194        | +             | +                   | +             | –                   |
| 195        | –             | –                   | +             | –                   |
| 200        | –             | –                   | +             | –                   |
| 210        | –             | –                   | +             | –                   |
| 212        | –             | +                   | –             | –                   |

* Samples 133 and 162 carry double discrepancies.

TABLE 5. Assessment of 24 atypical pANCA discrepant sera for additional IgG autoantibodies against other known neutrophil/nuclear antigens

| Sample no. | Prometheus pANCA | ARUP Result |
|------------|------------------|-------------|
| 10         | + (S)            | –           |
| 12         | + (S)            | –           |
| 15         | –                | –           |
| 21         | + (S)            | –           |
| 38         | + (S)            | –           |
| 50         | + (S)            | –           |
| 68         | + (S)            | –           |
| 73         | + (S)            | –           |
| 82         | + (S)            | –           |
| 93         | + (S)            | –           |
| 96b        | + (S)            | –           |
| 99         | + (S)            | –           |
| 104        | + (S)            | –           |
| 105        | + (S)            | –           |
| 106        | + (S)            | –           |
| 113        | + (S)            | –           |
| 123        | + (S)            | –           |
| 133        | + (S)            | –           |
| 139        | + (S)            | –           |
| 153        | –                | –           |
| 188        | + (S)            | –           |
| 212        | + (S)            | –           |
| 213        | + (S)            | –           |

* (S), DNase sensitive.

b Cytoplasmic pattern (cANCA) absent, as determined by both laboratories.

other known specific neutrophil/nuclear antigens (MPO, PR3, dsDNA, RNP, histone, and chromatin). Eleven of the 22 atypical pANCA discrepant sera by the DNase digest method (50.0%) gave positive antibody results for one or more of the six antigens tested (Table 5). The two atypical pANCA discrepant sera by the standard IFA method gave negative antibody results for all six antigens (Table 5). Cytoplasmic (cANCA) staining was not observed with any of these 24 discrepant sera.

Thirty-eight of 197 sera tested by Prometheus (19.3%) were positive for OmpC IgA. Twenty-five of these 38 sera (65.8%) were ASCA negative (IgA and IgG) as determined by Prometheus, while only 22 of 38 (57.9%) were ASCA negative as determined by ARUP. Three (no. 49, 133, and 135) of the 25 ASCA-negative/OmpC-positive sera detected by Prometheus (12.0%) were ASCA positive (one IgA, one IgG, and one IgA and IgG) by ARUP (Table 6). Twelve of the 25 (48.0%) ASCA-negative/OmpC-positive sera, as determined by Prometheus, were also positive for atypical pANCA (DNase sensitive), 9 of which (69.2%) were in agreement with the standard IFA performed at ARUP (Table 6), suggesting that these patients were more likely to have UC or Crohn’s colitis. Four of six (66.7%) patients in this group for whom clinical and biopsy information was available actually had UC (Table 7).

Of the 197 sera tested for OmpC IgA by Prometheus, only 9 (4.6%) had a positive OmpC result in the absence of other antibodies in IBD, and 8 of these had very low antibody content (16.8 to 22.8 EIA units [EU/ml]) (Table 6). The majority (19 of 25; 76.0%) of sera with ASCA-negative/OmpC-positive results as determined by Prometheus gave very low values
DISCUSSION

The ASCA and pANCA assays showed good agreement between the two reference laboratories (Tables 1 to 3). The Prometheus ASCA IgG assay, however, detected only 14 of the 32 positives (43.8%) determined by ARUP (Table 2). These findings are in agreement with a study from Belgium by Vermeire et al. (41), which showed the INOVA ASCA IgG assay to be 23% more sensitive than the ASCA IgG assay performed at Prometheus. Discord between these ASCA EIAs is most likely due to differences in their cutoff values, as was demonstrated in the study by Vermeire et al. using clinically defined sera (41).

Of the three assays compared between the two laboratories, the atypical pANCA IgG IFA had the most discrepancies. The DNase I digest method detected atypical pANCA in 22 additional sera, while the standard IFA method detected it in only 2 additional sera. Further assessment of these atypical pANCA discrepant sera for autoantibodies against other known neutrophil/nuclear antigens (MPO, PR3, dsDNA, RNP, histone, and chromatin) showed 50.0% of the DNase IFA discrepant sera to contain other autoantibodies against one or more of the specific antigens tested (Table 5). In contrast, the two discrepant sera by the standard IFA method gave negative results for all six additional markers (Table 5) and are more likely to be true atypical pANCA. The presence of antinuclear autoantibodies in patients with CD (18%) or UC (43%) has previously been reported (7). In addition, Reumaux et al. (27) detected IgG autoantibodies against several histone peptides primarily in patients with CD.

Since Prometheus utilizes a nonspecific ANCA (neutrophil) EIA for the screening of atypical pANCA, the presence of other autoantibodies as mentioned above could result in a positive ANCA EIA test that may affect the subsequent subjective neutrophil IFA pattern interpretation. Sera with strong homogeneous antinuclear reactivity could be misinterpreted as pANCA positive. If these specimens were then subjected to DNase digestion, sera with reactivity to dsDNA, histone, or chromatin (as shown to be the case for some of the atypical pANCA discrepant sera) would be interpreted as DNase sensitive. These results would be interpreted as supporting a diagnosis of ulcerative colitis when they are actually more likely to be false positives due to the presence of antibodies to other specific neutrophil/nuclear antigens. A serum that was positive for dsDNA antibody was a control (it was DNase sensitive) used in the study first describing the DNase IFA methodology for detecting atypical pANCA (42).

The reports for IBD testing from Prometheus indicate that the purpose of their ANCA (neutrophil) EIA is to validate positive pANCA IFA sera, meaning that both tests must be positive before the result is reported to be “IFA perinuclear pattern detected.” For sera that are ANCA EIA positive/pANCA IFA negative, “elevated levels” of ANCA IgG are reported. Sixteen of 140 pANCA IFA-negative sera were ANCA EIA positive, giving the Prometheus ANCA EIA a false-positive rate of 11.4%. These patients must then continue with the Prometheus “IBD Diagnostic System” or “IBD Confirmatory System” to determine if the “IBD First Step”-positive ANCA EIA result is actually due to atypical pANCA. Six of 57 (10.5%) Prometheus pANCA IFA-positive sera (all six DNase sensitive) were reported to be “IFA perinuclear pattern not detected” since they were ANCA EIA negative. Thus, the IBD reports from Prometheus indicate that false positives occur often (10.5% in this study) with their DNase digest IFA method for detecting pANCA.

Currently, the OmpC IgA assay is performed only at Prometheus, whose reports indicate that this assay detects an additional 21% of CD patients who are seronegative for ASCA (14). It should be noted that only 56% of their CD patients were found to be ASCA seropositive (14). IBD test reports

| TABLE 6. Results for 25 sera that were ASCA negative/OmpC positive as determined by Prometheus Laboratories |
| Sample no. | Prometheus OmpC IgA (EU/ml) | INOVA OMP IgA | ARUP ASCA IgA | ARUP ASCA IgG | ARUP pANCA IgG | Prometheus pANCA IgG |
|------------|-----------------------------|--------------|--------------|--------------|----------------|---------------------|
| 6          | 20.0 EQV                    |              |              |              | + (S)          |                     |
| 16         | 19.7                        |              |              |              |                |                     |
| 24         | 18.0 EQV                    |              |              |              |                |                     |
| 49         | 37.4                        |              |              |              |                |                     |
| 55         | 20.4 EQV                    |              |              |              | + (R)          |                     |
| 69         | 27.9                        |              |              |              | + (S)          |                     |
| 79         | 26.3                        |              |              |              |                |                     |
| 80         | 21.3                        |              |              |              |                |                     |
| 82         | 20.2                        |              |              |              |                |                     |
| 89         | 16.8                        |              |              |              |                |                     |
| 93         | 40.2                        |              |              |              |                |                     |
| 102        | 22.8                        |              |              |              |                |                     |
| 107        | 25.9                        |              |              |              | + (S)          |                     |
| 108        | 41.4                        |              |              |              | + (S)          |                     |
| 111        | 18.1                        |              |              |              |                |                     |
| 116        | 16.9 EQV                    |              |              |              |                |                     |
| 133        | >11.0 EQV                   |              |              |              |                |                     |
| 135        | 20.6                        |              |              |              | + (S)          |                     |
| 137        | 23.2 EQV                    |              |              |              |                |                     |
| 150        | 19.3                        |              |              |              |                |                     |
| 152        | 20.1                        |              |              |              | + (S)          |                     |
| 153        | 18.6                        |              |              |              |                |                     |
| 166        | 54.0                        |              |              |              |                |                     |
| 188        | 60.6                        |              |              |              |                |                     |
| 205        | 17.0 QNS                    |              |              |              |                |                     |

* 16.5 EU/ml or greater is considered positive.
* EQV, equivocal; QNS, quantity not sufficient.
* (S), DNase sensitive; (R), DNase resistant.

| TABLE 7. Diagnosis based on clinical and biopsy data for ASCA-negative/OmpC-positive patients for whom information was available |
| Sample no. | Age (yr) | Gender | Diagnosis |
|------------|----------|--------|-----------|
| 55         | 75       | Female | Ulcerative colitis |
| 80         | 30       | Female | Ulcerative colitis |
| 93         | 38       | Male   | Ulcerative colitis |
| 137        | 54       | Male   | Crohn’s disease |
| 152        | 45       | Male   | Ulcerative colitis |
| 166        | 61       | Female | Crohn’s disease |

* See Table 6 for IBD testing results.
from Prometheus show a positive predictive value of 85% for CD if OmpC IgA is the only positive result in their panel. If the results show OmpC positive/pANCA positive (DNase sensitive), the report states “results suggestive of ulcerative colitis.” Studies performed at Prometheus indicate that this pattern of results (ASCA negative/OmpC positive/pANCA positive) occurred two times more frequently in patients with UC than in those with Crohn’s disease. In view of this information and the data generated from this study, OmpC IgA appears to be more prevalent in UC, since many of the patients having ASCA-negative/OmpC-positive results were also atypical pANCA positive (Table 6). Of the limited number of patients who were ASCA negative/OmpC positive and from whom we were able to obtain clinical data (Table 7), 66.7% actually had ulcerative colitis, suggesting the limited diagnostic value of OmpC IgA in Crohn’s disease.

REFERENCES
1. Bansii, D. S., R. W. Chapman, and K. A. Fleming. 1996. Prevalence and diagnostic role of antibacterial pANCA antibodies in inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 8:881–885.
2. Bernstein, C. N., J. F. Blanchard, P. Rawsthorne, and J. A. Goeken. 1989. Epidemiology of Crohn’s disease in a central Canadian province: a population-based study. Am. J. Epidemiol. 139:916–924.
3. Canani, R. B., M. T. Romano, L. Greco, G. Terrin, C. Sferlazzas, A. Barabino, M. Fontana, P. Roggero, G. Guariso, G. De Angelis, S. Fecarotta, G. Polito, and S. Cucchiara. 2004. Effects of disease activity on anti-Saccharomyces cerevisiae antibodies: implications for diagnosis and follow-up of children with Crohn’s disease. Inflamm. Bowel Dis. 10:234–239.
4. Coche, J. C., and J. F. Colombel. 1998. Heterogeneity of inflammatory bowel disease: clinical subgroups of patients. Res. Clin. Forums 20:135–145.
5. Eggena, M., O. Cohavy, M. H. Parseghian, B. A. Hamkalo, D. Clemens, S. R. Targan, L. K. Gordon, and J. Braun. 2000. Identification of histone H1 as a cognate antigen of the ulcerative colitis-associated marker antibody pANCA. J. Autoimmun. 14:83–97.
6. Ellsir, Y., Z. Lawrence, and N. Tolvaynt. 2005. The diagnostic accuracy of serologic markers in children with IBD: the West Virginia experience. J. Clin. Gastroenterol. 39:670–673.
7. Folwaczny, C., N. Noehl, S. P. Endres, W. Heldwein, K. Loeschke, and H. Herfarth. 1999. Antibody to Saccharomyces cerevisiae mannan antibodies combined with anti-neutrophil cytoplasmic autoantibodies in inflammatory bowel disease prevalence and diagnostic role. Gut 42:788–791.
8. Panaccione, R., and W. J. Sanborn. 1998. Are antibody testing for inflammatory bowel disease clinically useful? Gastroenterology 116:1001–1008.
9. Quinton, J. F., S. Sendid, D. Reumaux, P. Duthilleul, A. Cortei, B. Grandbastien, G. Barrier, S. R. Targan, J. F. Colombel, and D. Poulain. 1996. Anti Saccharomyces cerevisiae mannan antibodies combined with anti-neutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 42:724–725.
10. Reumaux, D., C. Meziere, J. F. Colombel, P. Duthilleul, and S. Mueller. 1995. Distinct production of autoantibodies to nuclear components in ulcerative colitis and in Crohn’s disease. Clin. Immunol. Immunopathol. 77:349–357.
11. Roenouda, C., and C. G. Kallenberg. 1999. Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)? Clin. Exp. Immunol. 116:206–213.
12. Roenouda, C., K. Pogany, G. Horst, T. G. Jagt, J. H. Kleibeuker, G. F. Nolts, P. C. Limburg, and G. C. Kallenberg. 1999. Does analysis of the antigenic specificities of anti-neutrophil cytoplasmic antibodies contribute to their clinical significance in the inflammatory bowel diseases? Scand. J. Gastroenterol. 34:1123–1131.
13. Saibeni, S., C. Folli, R. de Franchis, G. Borsi, and M. Vecchi. 1999. Does analysis of the antigenic specificities of anti-neutrophil cytoplasmic antibodies contribute to their clinical significance in the inflammatory bowel diseases? Scand. J. Gastroenterol. 34:1123–1131.
14. Sendid, B., J. F. Colombel, C. Faille, J. Fruit, A. Cortot, D. Reumaux, D., C. Meziere, J. F. Colombel, P. Duthilleul, and S. Mueller. 1995. Distinct production of autoantibodies to nuclear components in ulcerative colitis and in Crohn’s disease. Clin. Immunol. Immunopathol. 77:349–357.
15. Seput, P., and S. Vermeire. 1998. Clinical value of the detection of antibodies in the serum for diagnosis and treatment of inflammatory bowel disease. Gastroenterology 115:1006–1022.
16. Saiten, C., S. Folli, R. de Franchis, G. Borsi, and M. Vecchi. 2003. Diagnostic role and clinical correlates of anti-Saccharomyces cerevisiae antibodies (ASCA) and anti-neutrophil cytoplasmic antibodies (p-ANCA) in Italian patients with inflammatory bowel disease. Dig. Liver Dis. 35:862–868.
17. Silbey, R. K., C. Mallant-Hent, Z. M. Groothuismink, L. E. Bakker-Jonges, J. P. van der Merwe, H. Hooijkaas, B. M. von Blomberg, and S. G. Meuwissen. 2002. Evaluation of serological markers to differentiate between ulcerative colitis and Crohn’s disease: pANCA, ASCA and agglutinating antibodies to anaerobic cocccoid rods. Eur. J. Gastroenterol. Hepatol. 14:1031–1038.
18. Loftus, E. V., Jr., M. D. Silverstein, W. J. Sandborn, W. J. Tremaine, W. S. Harison, and A. R. Zinsmeister. 1998. Crohn’s disease in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival. Gastroenterology 114:1161–1168.
19. Main, J., H. McKenzie, G. R. Yeaman, M. A. Kerr, D. Robson, C. R. Pennington, and D. Parnell. 1998. Antibody to Saccharomyces cerevisiae (baker’s yeast) in Crohn’s disease. BMJ 297:1105–1106.
20. McKenzie, H., J. Main, C. R. Pennington, and D. Parratt. 1990. Antibody to selected strains of Saccharomyces cerevisiae (baker’s and brewer’s yeast) and inflammatory bowel disease. Gut 31:253–257.
21. Meuwissen, M., M. R. Fabricantor, and W. S. Selby. 2002. Assessment and relevance of enzyme-linked immunosorbent assay for antibodies to Saccharomyces cerevisiae in Australian patients with inflammatory bowel disease. J. Intern. Med. 32:239–35.
clear fluorescence in chronic inflammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins. Hepatology 28:332–340.

39. Terjung, B., U. Spengler, T. Sauerbruch, and H. J. Worman. 2000. “Atypical p-ANCA” in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 119:310–322.

40. Vasiliauskas, E. A., S. E. Plevy, C. J. Landers, S. W. Binder, D. M. Ferguson, H. Yang, J. I. Rotter, A. Vidrich, and S. R. Targan. 1996. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn’s disease define a clinical subgroup. Gastroenterol. 6:1810–1819.

41. Vermeire, S., S. Joossens, M. Peeters, F. Monsuur, G. Marien, X. Bossuyt, P. Groenen, R. Vlieghe, and P. Rutgeerts. 2001. Comparative study of ASCA (anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology 120:827–833.

42. Vidrich, A., K. Lee, E. James, L. Cobb, and S. Targan. 1995. Segregation of pANCA antigenic recognition by DNase treatment of neutrophils: ulcerative colitis, type 1 autoimmune hepatitis, and primary sclerosing cholangitis. J. Clin. Immunol. 15:293–299.

43. Zholudev, A., D. Zurakowski, W. Young, A. Leichtner, and A. Bousvaros. 2004. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn’s disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am. J. Gastroenterol. 99:2235–2241.